CD38 and Miyoshi myopathy: In the retrospective MAMMOTH multi-center American study of patients with MM refractory to anti-CD38 mAbs who had received a median of 4 prior lines of therapy before the index regimen, the ORR was 31% and median PFS from initiation of subsequent therapy was 3.4, while the median OS from anti-CD38 mAb progression was 9.3 months [9].